Specialized nucleic acid LNP encapsulation services for mRNA, siRNA, ASO, pDNA, miRNA, circRNA, saRNA, and CRISPR-related payloads.
Lipid nanoparticles have become one of the most versatile delivery platforms for nucleic acid research, but efficient encapsulation is rarely achieved by simply mixing lipids and cargo. The final encapsulation profile depends on nucleic acid length, charge density, secondary structure, buffer composition, ionizable lipid behavior, flow conditions, aqueous-to-organic phase ratio, and post-formation processing. For pharmaceutical and biotechnology teams, the real challenge is not only obtaining a high encapsulation efficiency, but also producing LNPs with controlled particle size, narrow PDI, reproducible nucleic acid protection, and formulation attributes suitable for downstream biological evaluation. BOC Sciences provides nucleic acid LNP encapsulation services covering formulation design, microfluidic encapsulation, process parameter screening, payload-specific optimization, and analytical confirmation. Our service is designed to help researchers transform fragile nucleic acid molecules into stable, well-characterized LNP systems for discovery-stage, translational, and platform-development programs.
Different nucleic acid payloads behave very differently during LNP formation. Molecular length, strand structure, charge density, chemical modification, folding pattern, and sensitivity to shear stress can all influence encapsulation efficiency, particle size, colloidal stability, and biological performance. BOC Sciences provides payload-specific nucleic acid LNP encapsulation services, helping pharmaceutical and biotechnology researchers develop stable, well-characterized lipid nanoparticle formulations for diverse RNA and DNA delivery applications.
Messenger RNA is typically longer and more structurally fragile than small oligonucleotides, requiring carefully controlled formulation conditions to preserve RNA integrity while achieving high encapsulation efficiency. We develop mRNA LNP formulations for reporter expression, protein replacement research, antigen expression studies, and functional cell-based evaluation.
siRNA molecules are short, highly charged, and sensitive to incomplete complexation, making N/P ratio and lipid composition critical to formulation performance. We support siRNA LNP development for gene-silencing research, target validation, and cellular knockdown studies.
Antisense oligonucleotides may show different lipid-association behavior depending on sequence length, backbone chemistry, and chemical modifications. We develop ASO-loaded LNPs with attention to charge interaction, payload retention, and particle stability.
miRNA mimics and inhibitors often require precise encapsulation control because small changes in free nucleic acid content or particle heterogeneity may affect cellular response. We provide LNP encapsulation support for miRNA replacement, inhibition, and pathway-modulation studies.
Self-amplifying RNA is larger than conventional mRNA and can be more challenging to encapsulate due to its extended length and structural complexity. We design saRNA LNP encapsulation workflows that balance RNA protection, particle size control, and formulation reproducibility.
Circular RNA has a unique closed-loop structure that may influence folding, solution behavior, and lipid association during LNP formation. We develop circRNA LNP encapsulation conditions for expression research, stability studies, and comparative delivery evaluation.
Plasmid DNA presents formulation challenges related to large molecular size, topology, viscosity, and shear sensitivity. We support pDNA LNP encapsulation for gene-expression research and DNA delivery studies where controlled particle formation is essential.
CRISPR-related nucleic acid delivery may involve guide RNA, donor DNA, mRNA, or multi-component payload combinations. We provide feasibility assessment and formulation screening for LNP systems requiring co-encapsulation or sequential formulation design.
Successful nucleic acid LNP encapsulation depends on the coordinated control of formulation method, lipid-cargo interaction, colloidal stability, and analytical verification. BOC Sciences supports multiple encapsulation technologies and optimization strategies for RNA- and DNA-loaded lipid nanoparticles, helping researchers obtain reproducible LNP formulations with defined particle attributes and reliable nucleic acid protection.
Move from trial-and-error mixing to data-guided LNP encapsulation with controlled particle attributes and payload-specific analytical confirmation.
BOC Sciences provides flexible nucleic acid LNP encapsulation services according to formulation complexity, customization requirements, development stage, and expected deliverables. Whether clients need a rapid feasibility batch, a formulation comparison set, or a customized nucleic acid LNP system with defined analytical data, our team can design an appropriate service package based on payload properties and research objectives.
| Service Category | Supported LNP Systems, Customization Scope & Deliverables | Request Information |
|---|---|---|
| Standard Nucleic Acid LNP Encapsulation | Suitable for common RNA or DNA payloads requiring a practical starting formulation. We prepare LNPs using established lipid composition ranges and controlled mixing conditions, with deliverables including encapsulated LNP samples, basic particle size/PDI data, zeta potential when applicable, and encapsulation efficiency results. | Inquiry |
| Payload-Specific LNP Encapsulation | Designed for mRNA, siRNA, ASO, miRNA, circRNA, saRNA, pDNA, and CRISPR-related nucleic acids with distinct molecular length, charge density, modification pattern, or topology. Deliverables may include payload-matched formulation conditions, nucleic acid recovery data, free-cargo assessment, and recommendations for further optimization. | Inquiry |
| Customized Lipid Composition LNPs | Supports projects requiring tailored ionizable lipid, helper lipid, cholesterol, and PEG-lipid ratios. We can compare multiple lipid composition designs to evaluate encapsulation efficiency, particle size distribution, colloidal behavior, and suitability for downstream in vitro studies. | Inquiry |
| Targeted or Surface-Modified Nucleic Acid LNPs | For research programs requiring ligand-modified or surface-functionalized LNPs, we support formulation design involving PEG-lipid anchors, targeting ligands, peptides, antibodies, or small-molecule motifs. Deliverables focus on particle attribute confirmation, surface-modification feasibility, and nucleic acid encapsulation assessment. | Inquiry |
| Co-Encapsulated Nucleic Acid LNP Systems | Supports feasibility studies for LNPs carrying two or more nucleic acid components, such as mRNA plus guide RNA, siRNA combinations, guide RNA plus donor nucleic acid, or RNA/DNA co-formulations. We evaluate payload ratio, formulation compatibility, particle quality, and co-encapsulation feasibility. | Inquiry |
| Formulation Feasibility Screening | Suitable for early-stage projects where the optimal LNP condition is unknown. We screen selected lipid ratios, N/P ratios, buffer conditions, and microfluidic mixing parameters, then deliver comparative data to help clients select promising formulation candidates. | Inquiry |
| Encapsulation Optimization Package | Designed for projects with low EE%, broad PDI, aggregation, poor nucleic acid recovery, or inconsistent activity. Deliverables may include multi-condition formulation data, optimized encapsulation parameters, analytical comparison of candidate LNPs, and technical interpretation of key formulation bottlenecks. | Inquiry |
| Characterized LNP Sample Delivery | For clients requiring ready-to-use research samples, we provide formulated nucleic acid LNPs with supporting characterization data, including particle size, PDI, encapsulation efficiency, zeta potential when applicable, nucleic acid recovery, and formulation notes for downstream experimental planning. | Inquiry |
Nucleic acid LNP projects often fail because encapsulation efficiency, particle quality, and biological performance are optimized separately. We address formulation problems as interconnected variables.
✔ Low Encapsulation Efficiency
Free RNA or DNA may remain after mixing when lipid composition, N/P ratio, pH, or nucleic acid concentration is not matched to the payload. We screen formulation variables to improve encapsulation while tracking particle size and recovery.
✔ Particle Aggregation After Mixing
Aggregation can occur when nucleic acid charge is over-neutralized or when PEG-lipid, cholesterol, and helper lipid ratios are not balanced. We adjust lipid molar ratios and processing conditions to reduce large-particle formation.
✔ Broad PDI and Poor Batch Reproducibility
Mixing instability often produces variable particle size distributions. We optimize flow rate ratio, total flow rate, and phase composition to improve reproducibility across preparation runs.
✔ Nucleic Acid Degradation or Shear Sensitivity
Long RNA and plasmid DNA may be sensitive to processing stress. We design gentle formulation workflows, minimize unnecessary handling, and confirm payload integrity with suitable nucleic acid analysis methods.
✔ Free Cargo Interference in Bioassays
Residual free nucleic acid can distort cellular uptake, transfection, or knockdown data. We combine purification with encapsulation efficiency analysis to distinguish true LNP-mediated delivery from free-cargo artifacts.
✔ Inconsistent Activity Despite High EE%
High encapsulation efficiency alone does not guarantee functional delivery. We evaluate size, PDI, surface charge, payload integrity, and formulation composition to identify why apparently well-loaded LNPs perform poorly in in vitro models.
BOC Sciences provides practical experience in nucleic acid LNP encapsulation, microfluidic formulation, free-cargo analysis, and particle optimization to help researchers develop more stable and reproducible RNA/DNA-loaded LNP systems.
We review nucleic acid type, sequence length, concentration, buffer composition, modification status, and target particle attributes to define a realistic encapsulation strategy.
Lipid molar ratios, N/P ratio, buffer pH, total flow rate, flow rate ratio, and nucleic acid input concentration are screened to identify promising formulation windows.
Candidate LNPs are prepared under controlled mixing conditions, followed by removal of residual solvent, reduction of free nucleic acid, and exchange into a formulation-compatible buffer.
We report encapsulation efficiency, particle size, PDI, zeta potential, nucleic acid recovery, and key formulation observations to guide the next development decision.
Challenge: A research team developing a 4.2 kb reporter mRNA LNP observed acceptable RNA recovery but unstable particle quality. Initial batches showed particle sizes ranging from 120 to 230 nm and PDI values frequently above 0.30 after buffer exchange, making the formulation unsuitable for consistent in vitro expression comparison.
Diagnosis: The original mixing condition used a high RNA input concentration and a rapid buffer transition, which increased local charge heterogeneity during nanoparticle formation. Post-formulation concentration further amplified aggregation, especially in samples with insufficient PEG-lipid stabilization.
Solution: BOC Sciences designed a stepwise screening plan covering three N/P ratios, two PEG-lipid levels, and four microfluidic flow conditions. We first reduced RNA concentration during the mixing step to limit local over-complexation, then compared flow rate ratios to identify a narrower self-assembly window. A moderate PEG-lipid increase improved colloidal stability without excessively increasing particle size. Candidate LNPs were then purified using a gentler buffer exchange sequence, and each condition was assessed by encapsulation efficiency, DLS size, PDI, zeta potential, and RNA integrity analysis.
Result: The optimized condition produced mRNA LNPs with an average size of 86-105 nm, PDI below 0.18 across three preparation runs, and encapsulation efficiency above 90%. The client obtained a more consistent formulation set for comparative cellular expression studies.
Challenge: A biotechnology client working with a chemically modified 21-mer siRNA reported encapsulation efficiency below 55% and a high free-siRNA signal after purification. Increasing total lipid concentration improved EE% slightly but caused particle size drift above 180 nm.
Diagnosis: The siRNA showed incomplete association under the initial buffer pH and N/P ratio. At higher lipid concentrations, excessive charge neutralization promoted particle fusion and broad size distribution rather than improving true encapsulation.
Solution: Our team evaluated N/P ratios from 3 to 8, compared acetate- and citrate-based aqueous phases, and screened total flow rates to control early-stage nucleation. We also compared two ionizable lipid molar-ratio designs to determine whether stronger complexation or improved particle packing was more important for this sequence. Fluorescence accessibility assays were performed before and after detergent disruption to separate free siRNA from encapsulated siRNA, while DLS and zeta potential data were used to reject conditions with aggregation risk.
Result: The best-performing formulation reached 88-92% siRNA encapsulation efficiency while maintaining particle size around 75-95 nm and PDI below 0.20. Compared with the starting condition, the optimized formulation reduced free siRNA signal by more than 70% and provided a cleaner sample for downstream knockdown evaluation.
Payload-Specific Formulation LogicWe do not treat all nucleic acids as interchangeable cargo. mRNA, siRNA, ASO, pDNA, circRNA, saRNA, and CRISPR-related payloads are formulated according to their size, structure, and charge behavior.
Integrated CharacterizationEncapsulation results are interpreted together with nanoparticle size analysis, PDI, zeta potential, and nucleic acid recovery rather than as an isolated EE% value.
Process-Linked OptimizationOur workflow connects formulation composition with mixing parameters, purification conditions, and post-processing behavior to help identify robust preparation windows.
Free vs. Encapsulated Cargo DifferentiationWe apply fluorescence accessibility assays, detergent disruption, and separation-based measurements to distinguish surface-accessible or free nucleic acid from truly encapsulated payload.
Flexible Development ScopeProjects can focus on a single feasibility formulation, a multi-condition encapsulation screen, or a broader lipid nanoparticle formulation development program.
LNP encapsulation can support a broad range of nucleic acid payloads, including mRNA, siRNA, miRNA, saRNA, antisense oligonucleotides, plasmid DNA, circular RNA, and selected nucleic acid complexes. Each payload type behaves differently during LNP self-assembly because molecular length, charge density, secondary structure, buffer composition, and input concentration can all affect encapsulation efficiency, particle size, PDI, zeta potential, and leakage risk. For example, short siRNA molecules often rely strongly on charge-driven association with ionizable lipids, while long mRNA payloads require more careful control of shear exposure, structural integrity, and particle uniformity. BOC Sciences can design payload-specific formulation screening strategies to match nucleic acid properties with suitable lipid composition and microfluidic process parameters.
The main challenge in nucleic acid LNP encapsulation is not simply achieving high loading, but balancing encapsulation efficiency, particle quality, nucleic acid integrity, low free nucleic acid content, reproducibility, and downstream functional performance. Common issues include low encapsulation efficiency, oversized particles, broad PDI, nucleic acid degradation, leakage after dilution, inconsistent transfection or silencing results, and batch-to-batch variation. These problems may arise from ionizable lipid selection, N/P ratio, aqueous phase pH, flow rate ratio, total flow rate, nucleic acid concentration, ethanol dilution behavior, and post-formulation purification conditions. A successful formulation strategy should evaluate these variables together rather than treating loading, stability, and biological response as separate problems.
Improving nucleic acid encapsulation efficiency usually requires coordinated optimization of lipid composition, payload input conditions, and process parameters. Ionizable lipid-to-nucleic acid interaction is important, but simply increasing ionizable lipid content does not always improve the final formulation; excessive charge interaction may increase particle heterogeneity or affect release behavior. Helper lipid, cholesterol, and PEG-lipid ratios also influence particle nucleation, membrane stability, and payload retention. Microfluidic parameters such as flow rate ratio, total flow rate, aqueous-to-organic phase ratio, buffer pH, and nucleic acid concentration can strongly affect LNP self-assembly. BOC Sciences supports matrix-based formulation screening that compares encapsulation efficiency, particle size, PDI, zeta potential, free nucleic acid signal, and retention behavior to identify more suitable formulation conditions.
mRNA and siRNA are both negatively charged nucleic acids, but they behave very differently during LNP encapsulation. siRNA is shorter, more structurally uniform, and often easier to associate with ionizable lipids through charge-based complexation. mRNA is longer, more flexible, and more sensitive to shear stress, pH transition, interfacial exposure, and degradation, so formulation development must pay closer attention to RNA integrity, particle uniformity, and retained expression signal. mRNA LNPs often require more careful control of mixing stress, buffer conditions, and post-processing, while siRNA LNPs typically require balancing N/P ratio, intracellular release, and gene-silencing performance. Therefore, the same LNP formulation should not be automatically applied to both payload types without payload-specific optimization.
Nucleic acid LNP quality should be evaluated using both physicochemical characterization and application-relevant functional readouts. Core analytical items include particle size, PDI, zeta potential, encapsulation efficiency, free nucleic acid content, nucleic acid recovery, morphology, and retention after dilution or buffer exchange. For mRNA LNPs, additional attention may be given to RNA integrity and expression-related signals in suitable in vitro models. For siRNA or miRNA LNPs, uptake behavior, target gene knockdown, and dose-response trends may provide useful functional context. A strong candidate formulation should show controlled particle distribution, low free payload signal, acceptable nucleic acid retention, and interpretable biological performance. BOC Sciences integrates formulation development, encapsulation analysis, and particle characterization to help researchers connect formulation attributes with experimental outcomes.
